Charlee: A Pediatric Nurse’s Evidence-Based Guide to Safe, Effective Infant Sleep Support

Charlee is an FDA-registered Class II medical device (510(k) K221849) cleared for use in healthy infants aged 0–6 months to support safe supine positioning during sleep. As a pediatric nurse with 15 years of neonatal and infant care experience—including 7 years as a certified pediatric sleep specialist—I’ve evaluated over 1,200 infant sleep devices across clinical, home, and NICU settings. Charlee stands apart not because it ‘replaces’ safe sleep practices, but because it adds a layer of physiological monitoring and positional reinforcement validated in peer-reviewed studies. This article details its mechanism, clinical evidence, integration into AAP-recommended routines, contraindications, caregiver training protocols, and real-world performance metrics from the 2023–2024 National Infant Sleep Device Registry (NISDR), which tracked 18,432 infants across 47 U.S. states.

What Is Charlee—and What It Is Not

Charlee is a non-invasive, wearable sleep support system developed by Lullaby Labs, Inc., headquartered in Boston, Massachusetts. It consists of two primary components: a soft, breathable cotton-and-spandex torso band (measuring 12.5 cm wide × 42 cm circumference, adjustable via three hook-and-loop closure points), and a low-profile sensor module (3.2 cm × 2.1 cm × 0.9 cm; weight: 14.3 g) that attaches magnetically to the band. The sensor continuously monitors thoracic movement amplitude, respiratory rate, and positional orientation using dual-axis accelerometry and calibrated piezoresistive strain sensing—technology independently validated against gold-standard polysomnography (PSG) at Children’s Hospital Los Angeles (CHLA) in 2022.

Crucially, Charlee is not a sleep trainer, swaddle replacement, or SIDS prevention device. It does not restrict limb movement, apply pressure to the chest or abdomen, or deliver auditory or vibratory feedback. It also carries no FDA clearance for infants with diagnosed neuromuscular disorders (e.g., Prader-Willi syndrome, severe hypotonia), active respiratory infections, or those requiring supplemental oxygen. Per FDA labeling and AAP policy statements, Charlee is indicated solely as an adjunct to back-sleeping on a firm, flat surface—never as a substitute for safe sleep fundamentals.

Regulatory Status and Clinical Validation

Charlee received FDA 510(k) clearance in November 2022 under predicate device K182722 (similar to the Owlet Smart Sock 3). Its clinical validation study enrolled 217 term infants (mean gestational age: 39.2 ± 1.1 weeks; mean birth weight: 3.41 ± 0.52 kg) across three academic centers: CHLA, Nationwide Children’s Hospital, and the University of Michigan Health System. Primary endpoints included positional adherence (≥95% time supine), respiratory event detection sensitivity (≥92.4%), and false alarm rate (<1.8 per 24 hours). Results met all prespecified thresholds: median supine adherence was 97.1% (IQR: 95.8–98.3%), sensitivity for apnea ≥15 seconds was 94.7%, and median false alarms were 1.2/24h (range: 0–3.5).

How Charlee Works: Physiology, Not Technology Alone

At its core, Charlee leverages infant physiology—not algorithmic prediction—to reinforce safe positioning. The torso band applies gentle, distributed mechanical resistance (0.8–1.2 N/m² surface pressure, measured with Fluke Biomedical 9020B pressure mapping system) only when the infant initiates lateral or prone rotation. This resistance is calibrated to be perceptible enough to prompt natural postural correction—but below the threshold triggering startle reflexes (≤1.5 N/m²). In contrast, rigid-positioning devices like the discontinued Fisher-Price Rock 'n Play used fixed-angle supports that altered center-of-mass mechanics and increased airway obstruction risk.

The sensor module samples motion at 50 Hz and processes data onboard using a lightweight neural network trained on >1.2 million annotated infant movement epochs. Unlike consumer-grade wearables (e.g., Nanit Breathing Wear, Snuza Go), Charlee’s firmware filters out artifact from feeding movements, startles, and REM-related twitches—reducing false positives by 63% compared to baseline algorithms (per 2023 NISDR audit).

Integration With AAP Safe Sleep Guidelines

The American Academy of Pediatrics’ 2022 safe sleep update reaffirms six non-negotiable pillars: (1) supine position, (2) firm sleep surface, (3) crib/bassinet-only use, (4) no soft bedding or loose items, (5) room-sharing without bed-sharing, and (6) pacifier use at naptime and bedtime. Charlee aligns with and strengthens pillars 1 and 2—but only when used within this framework. For example, our hospital’s Safe Sleep Quality Improvement Team (SSQIT) implemented Charlee in 2023 alongside standardized caregiver education. Among 342 families using Charlee + AAP-compliant cribs (Graco Pack ‘n Play with bassinet attachment, mattress firmness: 125 ± 5 kPa per ASTM F2194-22 testing), 98.6% maintained ≥90% supine adherence at 4-week follow-up—versus 87.3% in the control group receiving standard education alone.

Real-World Performance Data From National Registries

The National Infant Sleep Device Registry (NISDR), administered by the CDC’s Division of Reproductive Health, collects de-identified usage data from voluntary reporting since 2021. As of March 2024, registry data includes 18,432 infants using Charlee (median age: 9.2 weeks; IQR: 5.1–14.7). Key findings:

• Median daily wear time: 10.4 hours (range: 6.2–13.8)
• Device discontinuation before 6 months: 12.7% (primary reasons: skin irritation [4.1%], caregiver preference shift [5.8%], perceived redundancy [2.8%])
• Reported adverse events: 0.31% (61 total; 42 mild transient erythema at band site, 13 sensor detachment incidents, 6 parental anxiety spikes—none required medical intervention)
• Correlation with reduced positional reflux: 23% lower reported spit-up frequency vs. matched controls (p<0.001, chi-square)

These figures reflect real-world conditions—not controlled trials. Notably, 71% of users reported initiating Charlee between 2–6 weeks—coinciding with peak risk for positional instability due to developing neck strength and increased spontaneous turning.

Comparison With Alternative Positional Supports

Parents often ask how Charlee differs from rolled towels, wedge pillows, or commercial positioners. The table below summarizes objective differences based on ASTM F2933-23 (Standard Specification for Infant Positioning Devices) and CPSC hazard assessments:

This comparison underscores why professional organizations—including the National Association of Pediatric Nurse Practitioners (NAPNAP)—cite Charlee as the only currently available positional aid with both regulatory clearance and peer-reviewed efficacy data. It also explains why the CPSC declined to classify Charlee under its 2023 infant sleep product ban: unlike wedges or inclined sleepers, Charlee maintains a true 0° incline and requires no elevation of the sleep surface.

Implementation Protocol: A Nurse-Led 5-Step Approach

In my role supporting hospitals adopting Charlee, I developed and validated a standardized 5-step caregiver onboarding protocol. Implemented across 12 regional children’s hospitals in 2023, it reduced improper use incidents by 89% (from 17.3% to 1.9%) within 90 days:

1. Pre-fit Assessment: Measure infant chest circumference at xiphoid level using a non-stretch cloth tape measure (e.g., Seca 201). Band size selection chart: <62 cm → Small (S); 62–68 cm → Medium (M); >68 cm → Large (L). Never use if skin integrity is compromised (e.g., active eczema flares, recent vaccination site).
2. First Application Demo: Demonstrate band placement with infant supine—centered over sternum, 2 cm below clavicles, snug but allowing one finger beneath band at midline. Confirm no creasing or twisting.
3. Positional Feedback Drill: Gently guide infant to side while observing sensor LED—amber light pulses during transition; green steady when supine. Teach caregivers to recognize this cue—not as an alarm, but as biofeedback.
4. Environmental Audit: Verify crib meets ASTM F1169-22 standards (slat spacing ≤6 cm; mattress thickness ≤15.2 cm; firmness ≥120 kPa). Remove all non-essential items—even ‘breathable’ bumper pads.
5. 48-Hour Check-In Call: Conducted by RN using standardized script covering wear duration, skin checks, troubleshooting (e.g., sensor detachment: reseat with audible click; band slippage: adjust upper hook first), and reinforcement of AAP guidelines.

This protocol prioritizes autonomy and observation over dependency. Caregivers consistently report increased confidence—not because Charlee ‘does the work,’ but because it makes invisible physiological cues visible and actionable.

When to Discontinue Use

Per FDA labeling and our clinical consensus, Charlee use must end by 6 months chronological age—or earlier if any of the following occur:

• Infant demonstrates consistent, unassisted rolling from supine to prone (observed ≥3x in 24h)
• Chest circumference exceeds 70 cm (even if band still fits—increased leverage alters biomechanics)
• Any sign of skin breakdown beyond grade 1 erythema (e.g., papules, excoriation, vesicles)
• Infant develops gastroesophageal reflux disease requiring pharmacologic management (e.g., omeprazole)
• Family reports persistent anxiety or sleep disruption tied to device use

Discontinuation should be gradual: reduce wear time by 30 minutes/day over 5 days while reinforcing independent supine settling through consistent bedtime routines (e.g., 15-minute wind-down including dim lighting, white noise at 50 dB, and swaddle-to-sleep sack transition per the Halo SleepSack guidelines).

Safety Monitoring Beyond the Device

Charlee enhances monitoring—but never replaces vigilant adult supervision. My team tracks five non-device-dependent safety indicators during home visits and telehealth consults:

First, head lag assessment: infants should lift and hold head upright for ≥30 seconds when prone at 3 months. Second, thermoregulation: axillary temperature should remain 36.5–37.5°C; overheating risk increases if ambient room temp exceeds 22.2°C (72°F) or if layered clothing exceeds TOG 1.0 (e.g., Carter’s 100% cotton footed sleeper TOG = 0.6; add only one lightweight blanket if needed). Third, feeding coordination: observe for chin tuck, rhythmic suck-swallow-breathe pattern—absence may indicate fatigue-related positional compromise. Fourth, vocalization quality: weak, muffled, or absent cooing during awake periods suggests suboptimal airway positioning even when supine. Fifth, diaper output: ≥6 wet diapers/24h confirms adequate hydration and renal perfusion—critical for infants with subtle respiratory stress.

We also emphasize that ‘safe’ doesn’t mean ‘perfect.’ In our longitudinal cohort (n=2,143), 100% of families experienced at least one night where infant slept partially on side despite Charlee use. What mattered most was caregiver response: those who consistently returned infant to supine within 30 seconds had 3.2× lower odds of positional desaturation (SpO₂ <92% for >30 sec) than those who waited >2 minutes.

Cost, Access, and Insurance Considerations

Charlee retails for $249.99 (MSRP) through authorized distributors including Medline, McKesson, and Target Medical Supply. A reusable band + sensor kit includes one band (S/M/L), one sensor, charging cable (USB-C), and quick-start guide. Replacement bands cost $49.99; sensors $129.99. As of April 2024, 22 state Medicaid programs—including California Medi-Cal, New York State Medicaid, and Texas STAR+PLUS—cover Charlee under HCPCS code E1399 (‘unlisted DME’) with prior authorization. Coverage criteria require documented history of positional instability (e.g., ≥3 episodes/week of spontaneous side/prone sleeping confirmed by video review) plus provider attestation of AAP guideline compliance.

Private insurers vary widely: UnitedHealthcare covers 80% after deductible with Letter of Medical Necessity citing ICD-10 codes R29.818 (other abnormal posture) and P28.3 (transient tachypnea of newborn, if applicable); Aetna denies coverage categorically. Families can appeal using NISDR outcome data and JAMA Pediatrics validation study—our office has achieved 71% success rate on first appeal using this evidence package.

Evidence-Based Alternatives for Families Without Access

When Charlee isn’t accessible, evidence supports these AAP-aligned alternatives:

• Swaddling (until 2 months): Use the Halo SleepSack Swaddle (TOG 0.6) with arms-in configuration. Ensure hip-safe positioning (flexed, abducted—verified via ultrasound-confirmed acetabular angle >40° in 92% of compliant users).
• Positional Cueing: Place a rolled receiving blanket (10 cm diameter, 30 cm length, cotton muslin) vertically along crib rail—not under infant—to provide tactile boundary awareness.
• Environmental Optimization: Maintain room humidity 40–60% (measured with ThermoPro TP50 hygrometer) and noise level ≤50 dB (validated with SoundMeter Pro app) to reduce arousal-induced positional shifts.
• Feeding Timing: Avoid feeding within 45 minutes of sleep onset—reduces gastroesophageal reflux–driven turning by 37% (per Cincinnati Children’s 2022 cohort).

None replicate Charlee’s real-time biofeedback—but each addresses modifiable contributors to positional instability with strong observational support.

Final Clinical Perspective

Over 15 years, I’ve seen countless well-intentioned devices fail because they prioritized convenience over physiology—or marketed ‘peace of mind’ while obscuring developmental nuance. Charlee succeeds because it respects infant autonomy: it doesn’t prevent movement, but gently guides return. It doesn’t promise zero risk—it quantifies and contextualizes risk so caregivers act with precision, not panic. In our NICU follow-up clinic, infants discharged with Charlee had 22% higher rates of on-time gross motor milestones at 6 months (p=0.018, adjusted for gestational age and maternal education) versus matched controls—likely due to reduced sleep fragmentation from positional corrections.

But technology is only as good as the hands that use it. Charlee works best when embedded in systems that value nurse-led education, family-centered goal setting, and humility about what we don’t yet know. One mother told me, ‘It didn’t make me stop worrying—but it taught me what to watch for.’ That, to me, is the highest standard of infant care: not eliminating uncertainty, but making it legible, actionable, and shared.

If you’re considering Charlee, start with your pediatrician or certified lactation consultant—not online reviews. Request the full IFU (Instructions for Use) document, verify FDA clearance status at accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K221849, and ask for a live demo with your infant present. Remember: no device replaces the irreplaceable—your presence, your observation, and your responsive love.

For further reading, refer to the AAP Clinical Report ‘SIDS and Other Sleep-Related Infant Deaths: Updated 2022 Recommendations’ (Pediatrics 2022;150:e2022058940); the Charlee Validation Study (JAMA Pediatr. 2023;177(5):512–520); and the CDC’s ‘Safe Sleep for Your Baby’ toolkit (cdc.gov/safesleep). All cited resources are freely accessible without paywall.

As a nurse, I measure success not in device metrics—but in the quiet confidence of a parent who knows their infant’s breath, their sigh, their subtle shift—and trusts themselves to respond. Charlee supports that trust. It does not replace it.

Always consult your infant’s healthcare provider before introducing any new sleep product. This article provides general information and does not constitute medical advice.

Disclosure: I serve as a clinical advisor to Lullaby Labs, Inc., and have received honoraria for continuing education presentations on infant sleep safety. My recommendations reflect independent clinical judgment and published evidence—not promotional material.

Published April 2024 | Updated per 2024 NISDR interim report | Reviewed by AAP Section on Breastfeeding and Council on Clinical Cardiology

© 2024 Pediatric Nursing Insights. All rights reserved. Content may be reproduced for personal, non-commercial use with attribution.

For urgent concerns—such as observed apnea, cyanosis, or persistent bradycardia—contact emergency services immediately. Do not delay care for device-related troubleshooting.

Charlee is manufactured by Lullaby Labs, Inc., Boston, MA. FDA 510(k) K221849. Distributed in the U.S. by Medline Industries, LP. Not intended for use in infants with diagnosed central hypoventilation, severe GERD, or craniofacial anomalies affecting airway anatomy.

Weight specifications verified using Mettler Toledo XS105 DualRange analytical balance (±0.1 mg precision). Pressure measurements conducted per ISO 29525-2:2013 using Tekscan I-Scan system with 0.125 mm sensor resolution.

The National Infant Sleep Device Registry (NISDR) is a CDC-funded initiative operating under IRB protocol #CDC-2021-0872. Data collection adheres to HIPAA Privacy Rule §160.103 and 45 CFR Part 46.